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Nanomedicine is a reality of medical research and clinical practice, 
and it offers new and promising approaches to fundamental 
problems in medicine. Most  prominent are the early detection of 
neoplastic disease and the  individualized treatment of metastases. 
These potentially transformational  developments require careful 
scrutiny of the potential impact of nanomedicine  on society, so 
that the community can guide its deployment in keeping with the  
fundamental tenets of medical ethics.
Definitions of nanotechnology abound, 
including several used by US and inter-
national agencies. The various definitions 
have three substantially common ele-
ments: nanotechnological devices are at 
least partly man-made, have dimensions 
on the scale of 1 to 1,000 nm, and possess 
novel “emerging” properties stemming 
from their nanoscale dimension—that 
is, properties not present in identical 
devices of smaller or larger dimensions. 
The existence of a mechanism-based, 
predictive proof of the causal necessity 
of the new properties is also required by 
some authors as part of the definition of 
nano technology. In the working defini-
tion we use in this article, nanomedicine 
is the application of nanotechnology to 
medicine, from basic research to disease 
diagnosis to therapeutic intervention, 
monitoring disease progression and 
patient management, including quality-
of-life measures.
Although this article neither subscribes 
to a consensus definition nor provides one 
for full adoption, it is consistent with the 
ones in common use, such as the one used 
by the National Nanotechnology Initia-
tive1 (to reduce ambiguity and misinter-
pretation). Furthermore, in the context of 
regulatory issues, as the science evolves 
and the US Food and Drug Administra-
tion (FDA) learns more about the interac-
tion of nanoscale materials with complex 
biological systems, the agency may develop 
formal, fixed definitions, appropriately tai-
lored to the regulation of nanoscale mate-
rials in FDA-regulated products.2
The promise of personalized nano-
medicine was based on the understand-
ing that each individual possesses a 
unique genetic profile predisposing him 
or her to respond to therapies differently. 
Now, armed with the predictive power of 
in silico models of patient populations, 
whole-genome testing, clinically quali-
fied biomarkers that can assess individual 
responses to therapies, and other tools, 
the biomedical field is poised for signifi-
cant advances and benefits to individu-
als rather than to their population mean. 
Nanomedicine, like no other field in sci-
ence, has the potential of interpretative 
flexibility—flexibility in how scientists 
design, analyze, and interpret outcomes. 
The marriage of genomics, postgenomics, 
and nanomedicine offers the potential for 
disruptive innovation and therapies tar-
geted to an individual.
“Nanomedicine” is a broad term that 
encompasses the development of sensors 
for single-molecule detection, identifica-
tion of biomarkers, nanoparticles and 
nanocarriers for the detection and imag-
ing of cancers, and the delivery of thera-
peutic molecules. Nanoparticle-based 
vehicles have also been used to deliver 
recombinant proteins as vaccines. In the 
area of therapeutic and imaging modali-
ties, the overwhelming majority of recent 
developments have been aimed at cancer. 
Materials that have been investigated for 
their utility include soft and liquid poly-
mers, polymers based on sugars or amino 
acids or both, liposomes, dendrimers, 
and metalloid/metallic and solid/hollow 
native or organically modified silicas. 
Such nanomaterials may be either per-
sistent or biodegradable.
Despite the wide range of materials 
and potential applications, most medici-
nal nanoparticles are essentially targeted 
carriers or “smart” polymers that deliver 
drugs, imaging agents, and/or chemicals 
that disrupt growth of cancer cells.3 Some 
nanomaterials use peptides and other 
ligands to actively target the appropriate 
site,4 and others are passively targeted by 
exploiting the pathophysiological changes 
that occur in increased permeability of 
blood vessels or other cellular phenom-
ena. The use of targeting antibodies, pep-
tides, and other targeting moieties on the 
surface lends itself to personalized medi-
cine. The fast-approaching capability to 
quickly identify unique surface markers 
on tumor cells and to design or fabricate 
a tailored nanomaterial that will attach 
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the patient’s right to decide), and justice 
(including fair access to health care).
The main conclusions of the pre-
sentation are summarized as follows. 
Nanotechnology offers extraordinary 
opportunities for medical advances and, 
most important, offers new hope for early 
detection and individualized therapy 
of disease. Environmental risks from 
nanomedicine are very modest. Nano-
technology-enabled personalized medi-
cine poses ethical questions of autonomy 
and privacy that must be discussed in the 
broadest community context for proper 
policy decisions to be made.
Nanomedicine is at risk of being avail-
able only to privileged societies, at least 
initially, but it offers unexplored oppor-
tunities for medical advances that would 
benefit underprivileged populations. 
The final, overarching conclusion is that 
careful scrutiny of potential safety risks 
is absolutely necessary—yet the greatest 
risk in nanomedicine may well be in let-
ting our concerns paralyze our action and 
not taking advantage of the full, revolu-
tionary potential that nanotechnology in 
medicine can offer humankind. We fully 
echo this conclusion.
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manifests itself, even in a single person, 
in the course of neoplastic disease.
These are exactly the two fronts on 
which nanomedicine provides its most 
promising weaponry.5 On the side of early 
detection, nanomedicine is evolving a host 
of new approaches that will allow for the 
rapid, non- or minimally invasive and 
inexpensive testing of a very large number 
of molecular signatures from biological 
fluids. Together with the development 
of new, molecularly targeted nanoscale 
contrast agents for radiological imaging, 
these are envisioned to aid in the birth of 
a new era of medical care, in which can-
cer screening is available to all and afford-
able for all. In view of the variability and 
diversity of the molecular presentations of 
metastatic disease, not only is the notion 
of “personalizing” treatment a good idea; 
it is a probably a necessary route to the 
eradication of death and suffering due 
to cancer. The need is even more radical: 
beyond personalization, what is required 
in many cases is treatment individualiza-
tion, at the level of the individual lesion. 
Here nanotechnology offers the opportu-
nity to develop new approaches, individu-
alizing treatment simultaneously on three 
fronts: (i) the bioactive payload, which 
can be, e.g., a “molecularly targeted” drug, 
short interfering RNA, or microRNA; (ii) 
the design of the carrier nanoparticle, 
which could be tailored to the immune 
responses of a patient; and, again, (iii) the 
design of the carrier particulate system, 
which can be tailored so as to optimize 
the likelihood of selective concentration 
in the target lesion.6
Research with the intent of translation 
into the clinic may be viewed within the 
classical medical ethics framework of 
Childress and Beauchamp. This perspec-
tive was used by the first author of this 
article in his presentation to the US Presi-
dent’s Council on Bioethics on 29 June 
2007, in the first (and so far only) ses-
sion dedicated by the council to matters 
of nanotechnology and nanomedicine.7 
The presentation reflected the four car-
dinal dimensions of analysis in the Beau-
champ–Childress system: beneficence 
(the utilitarian perspective of maximiz-
ing community benefit), nonmaleficence 
(the Hippocratic mandate of “First, do no 
harm”), respect (including autonomy, or 
itself with high affinity and selectivity 
will further enhance the attractiveness 
of using nanoparticles in imaging and 
therapeutic modalities. Moreover, sev-
eral of these nanostructures lend them-
selves to screening in situ. Because many 
of the imaging nanomaterials, and all the 
therapeutic ones, are designed for launch-
ing to various compartments within the 
body, several consequent physiological 
challenges arise. Chief among these chal-
lenges is the somewhat predictable inter-
play between a complex bionanoparticle 
and the immune system.
All the advantages of this approach 
notwithstanding—and precisely because 
most of the useful therapeutic and 
nanoparticles (5–150 nm diameter) 
range in size from that of a typical rhi-
novirus (~20 nm diameter) to that of 
the pox virus Molluscum contagiosum 
(~200 nm diameter)—they are targeted 
by the immune system of the host. The 
potential for accumulation of complex, 
bioactive mixtures of nanomaterial and 
adherent peptides raises questions about 
acute or chronic idiopathic adverse reac-
tions that may constitute a rare or under-
diagnosed condition. Certainly, the era 
of nano medicine will require extensive 
characterization of the therapeutic index 
during development and vigilant after-
market surveillance.
On the side of the potential beneficial 
impact on society, considerations about 
the importance of nanomedicine must be 
placed in the context of the health prob-
lems they address. Focusing attention on 
oncology, it is recalled that in the United 
States a person dies of cancer approxi-
mately every minute, and the worldwide 
number is more than five times that. 
The dimensions of the tragedy have not 
decreased in recent years in the United 
States and Europe, despite extraordinary 
advances in the molecular-level under-
standing of the disease. Two crucial rea-
sons for this failure to translate to basic 
progress in the clinic are: (i) the current 
inability to detect the disease at its earliest 
stages, when treatments are most effective 
and have the fewest adverse side effects, 
and (ii) the current inability to treat met-
astatic disease—in particular, due to the 
extraordinary, time-variable diversity of 
molecular connotations with which it 
